Quantcast

Latest Multiple drug resistance Stories

2014-09-16 08:30:15

Funding to Support Development of New Treatments for Drug-Resistant Gram-Negative Bacterial Infections OKLAHOMA CITY, Sept. 16, 2014 /PRNewswire/ -- Synereca Pharmaceutics, Inc. (SPI), a research-stage biopharmaceutical company developing novel orally active drugs that restore or increase the effectiveness of existing antibiotics, announced today a $1.4 million convertible debt financing. Accele Venture Partners, the investing arm of life sciences accelerator Accele Biopharma, Inc.,...

2014-09-08 12:29:24

Oral presentation and nine posters presented at ICAAC WASHINGTON, Sept. 8, 2014 /PRNewswire/ -- Findings reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) showed Shionogi's novel parenteral siderophore cephalosporin, S-694266, to exhibit marked potency against Gram-negative bacteria listed by the Centers for Disease Control and Prevention (CDC) at the urgent or serious level including multidrug-resistant Pseudomonas (MDRP),...

2014-09-03 16:25:49

LONDON, Sept. 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Antibiotics, medicinal plants, superbugs and the coming antimicrobial resistant drugs pandemic : global markets, competitors and opportuninites - 2014 - 2019 Analysis and...

2014-09-03 04:21:58

VIENNA, September 3, 2014 /PRNewswire/ -- New US Subsidiary to be located in the Philadelphia Area Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative pathogens, today announced the appointment of Dr Colin Broom as Chief Executive Officer (CEO). Current CEO Ralf Schmid will remain a member of the...

2014-06-19 08:28:10

Carbapenem Resistance Consortium Includes AstraZeneca, Cepheid, Cubist, and GSK SUNNYVALE, Calif., June 19, 2014 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced a new collaboration with AstraZeneca, Cubist Pharmaceuticals, Inc., and GSK intended to promote transformational change in infectious disease therapy by developing a rapid diagnostic test that can target multi-drug resistant pathogens and support the appropriate use of antibiotics. Targeting bacterial infections with the right...

2014-06-18 23:07:41

According to a new report from BCC Research, the global market for systemic antibiotics is expected to grow to $41.2 billion by 2018 with a compound annual growth rate (CAGR) of 0.8% between 2013 through 2018. Asian countries account for the fastest-growing market with a five-year CAGR of 1.2% due to the increasing aging population, increasing GDP rate and increasing awareness about healthcare. Wellesley, MA (PRWEB) June 18, 2014 BCC Research (http://www.bccresearch.com) reveals in its...

2014-06-16 08:27:47

On-demand molecular test detects and differentiates the genes encoding the most prevalent carbapenemases: KPC, NDM, VIM, OXA-48 and IMP-1 SUNNYVALE, Calif., June 16, 2014 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced the release of Xpert(®) Carba-R, an on-demand molecular test for rapid and accurate detection of carbapenemase-producing Gram-negative bacteria, to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on...

2014-05-15 12:36:52

Carbapenems Are Increasingly Being Deployed as Frontline Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., May 15, 2014 /PRNewswire/ -- Decision Resources Group finds that the majority of surveyed hospital-based infectious disease and critical/intensive care specialists in the EU5 (France, Germany, Italy, Spain and the United Kingdom) reported increases in infection rates due to key drug-resistant Gram-negative pathogens (GNPs) over the past two years. Further,...

2014-05-15 08:33:57

- Test Quickly Determines Colonization Risk of Multi-drug Resistant Microbes with Greater Accuracy than Currently Available Options - GAITHERSBURG, Md., May 15, 2014 /PRNewswire/ -- OpGen, Inc., a Gaithersburg based molecular diagnostics company, announced today that it has launched a new molecular-based test that can quickly and reliably identify patients at risk for harboring serious disease-causing microbes that can resist even the strongest antibiotics. The Acuitas(TM) MDRO Gene...

2014-04-23 12:30:07

Emerging Therapies Active Against Multidrug-Resistant Pathogens Will Be Preferred Over Generic Carbapenems, According to Findings from Decision Resources Group BURLINGTON, Mass., April 23, 2014 /PRNewswire/ -- Decision Resources Group finds that two emerging therapies in late-stage clinical development--AstraZeneca/Forest Laboratories' ceftazidime-avibactam and Tetraphase's eravacycline--will replace carbapenems as preferred therapies for treatment of gram-negative infections (GNIs) due to...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related